
    
      This phase 2 study will test the efficacy of short-term transdermal nicotine transdermal
      patch administration in patients who have been diagnosed with CIPN. The study will follow an
      open-label, crossover within-subjects clinical trial design with nicotine transdermal patch.
    
  